Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 58

1.

Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study.

Villa E, Critelli R, Lei B, Marzocchi G, Cammà C, Giannelli G, Pontisso P, Cabibbo G, Enea M, Colopi S, Caporali C, Pollicino T, Milosa F, Karampatou A, Todesca P, Bertolini E, Maccio L, Martinez-Chantar ML, Turola E, Del Buono M, De Maria N, Ballestri S, Schepis F, Loria P, Enrico Gerunda G, Losi L, Cillo U.

Gut. 2016 May;65(5):861-9. doi: 10.1136/gutjnl-2014-308483. Epub 2015 Feb 9.

PMID:
25666192
2.

Lymphoepithelioma-like hepatocellular carcinoma: an uncommon variant of hepatocellular carcinoma with favorable outcome.

Chan AW, Tong JH, Pan Y, Chan SL, Wong GL, Wong VW, Lai PB, To KF.

Am J Surg Pathol. 2015 Mar;39(3):304-12. doi: 10.1097/PAS.0000000000000376.

PMID:
25675010
3.

Serum microRNA-1 and microRNA-122 are prognostic markers in patients with hepatocellular carcinoma.

Köberle V, Kronenberger B, Pleli T, Trojan J, Imelmann E, Peveling-Oberhag J, Welker MW, Elhendawy M, Zeuzem S, Piiper A, Waidmann O.

Eur J Cancer. 2013 Nov;49(16):3442-9. doi: 10.1016/j.ejca.2013.06.002. Epub 2013 Jun 26.

PMID:
23810247
4.

Serum insulin-like growth factor-I level is an independent predictor of recurrence and survival in early hepatocellular carcinoma: a prospective cohort study.

Cho EJ, Lee JH, Yoo JJ, Choi WM, Lee MJ, Cho Y, Lee DH, Lee YB, Kwon JH, Yu SJ, Lee JM, Suh KS, Kim K, Kim YJ, Yoon JH, Kim CY, Lee HS.

Clin Cancer Res. 2013 Aug 1;19(15):4218-27. doi: 10.1158/1078-0432.CCR-12-3443. Epub 2013 Jun 11.

5.

A morpho-molecular prognostic model for hepatocellular carcinoma.

Srivastava S, Wong KF, Ong CW, Huak CY, Yeoh KG, Teh M, Luk JM, Salto-Tellez M.

Br J Cancer. 2012 Jul 10;107(2):334-9. doi: 10.1038/bjc.2012.230. Epub 2012 Jun 19.

6.

Overexpression of pituitary tumor transforming gene 1 in HCC is associated with angiogenesis and poor prognosis.

Fujii T, Nomoto S, Koshikawa K, Yatabe Y, Teshigawara O, Mori T, Inoue S, Takeda S, Nakao A.

Hepatology. 2006 Jun;43(6):1267-75.

PMID:
16628605
7.

Downregulation of ARNT2 promotes tumor growth and predicts poor prognosis in human hepatocellular carcinoma.

Li W, Liang Y, Yang B, Sun H, Wu W.

J Gastroenterol Hepatol. 2015 Jun;30(6):1085-93. doi: 10.1111/jgh.12905.

PMID:
25611915
8.

Overexpression of matrix metalloproteinase-12 (MMP-12) correlates with poor prognosis of hepatocellular carcinoma.

Ng KT, Qi X, Kong KL, Cheung BY, Lo CM, Poon RT, Fan ST, Man K.

Eur J Cancer. 2011 Oct;47(15):2299-305. doi: 10.1016/j.ejca.2011.05.032. Epub 2011 Jun 15.

PMID:
21683576
9.
10.

Upregulation of heat shock proteins (HSPA12A, HSP90B1, HSPA4, HSPA5 and HSPA6) in tumour tissues is associated with poor outcomes from HBV-related early-stage hepatocellular carcinoma.

Yang Z, Zhuang L, Szatmary P, Wen L, Sun H, Lu Y, Xu Q, Chen X.

Int J Med Sci. 2015 Feb 15;12(3):256-63. doi: 10.7150/ijms.10735. eCollection 2015.

11.

Tumor-stroma ratio is a prognostic factor for survival in hepatocellular carcinoma patients after liver resection or transplantation.

Lv Z, Cai X, Weng X, Xiao H, Du C, Cheng J, Zhou L, Xie H, Sun K, Wu J, Zheng S.

Surgery. 2015 Jul;158(1):142-50. doi: 10.1016/j.surg.2015.02.013. Epub 2015 Apr 15.

PMID:
25890776
12.

Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.

Lu LL, Sun J, Lai JJ, Jiang Y, Bai LH, Zhang LD.

World J Gastroenterol. 2015 Jun 7;21(21):6649-59. doi: 10.3748/wjg.v21.i21.6649.

13.

Molecular cytogenetic evaluation of virus-associated and non-viral hepatocellular carcinoma: analysis of 26 carcinomas and 12 concurrent dysplasias.

Zondervan PE, Wink J, Alers JC, IJzermans JN, Schalm SW, de Man RA, van Dekken H.

J Pathol. 2000 Oct;192(2):207-15.

PMID:
11004697
14.

CXCL17 expression predicts poor prognosis and correlates with adverse immune infiltration in hepatocellular carcinoma.

Li L, Yan J, Xu J, Liu CQ, Zhen ZJ, Chen HW, Ji Y, Wu ZP, Hu JY, Zheng L, Lau WY.

PLoS One. 2014 Oct 10;9(10):e110064. doi: 10.1371/journal.pone.0110064. eCollection 2014.

15.

High expression of transcriptional coactivator p300 correlates with aggressive features and poor prognosis of hepatocellular carcinoma.

Li M, Luo RZ, Chen JW, Cao Y, Lu JB, He JH, Wu QL, Cai MY.

J Transl Med. 2011 Jan 5;9:5. doi: 10.1186/1479-5876-9-5.

16.

A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.

Agopian VG, Harlander-Locke M, Zarrinpar A, Kaldas FM, Farmer DG, Yersiz H, Finn RS, Tong M, Hiatt JR, Busuttil RW.

J Am Coll Surg. 2015 Apr;220(4):416-27. doi: 10.1016/j.jamcollsurg.2014.12.025. Epub 2014 Dec 27.

PMID:
25690672
17.

Predictors of long-term survival after liver transplantation for hepatocellular carcinoma.

Zavaglia C, De Carlis L, Alberti AB, Minola E, Belli LS, Slim AO, Airoldi A, Giacomoni A, Rondinara G, Tinelli C, Forti D, Pinzello G.

Am J Gastroenterol. 2005 Dec;100(12):2708-16.

PMID:
16393224
18.

Loss of SFRP1 Expression Is Associated with Poor Prognosis in Hepatocellular Carcinoma.

Davaadorj M, Imura S, Saito YU, Morine Y, Ikemoto T, Yamada S, Takasu C, Hiroki T, Yoshikawa M, Shimada M.

Anticancer Res. 2016 Feb;36(2):659-64.

PMID:
26851021
19.

Wilms' tumour 1 gene expression is increased in hepatocellular carcinoma and associated with poor prognosis.

Sera T, Hiasa Y, Mashiba T, Tokumoto Y, Hirooka M, Konishi I, Matsuura B, Michitaka K, Udaka K, Onji M.

Eur J Cancer. 2008 Mar;44(4):600-8. doi: 10.1016/j.ejca.2008.01.008. Epub 2008 Feb 5.

PMID:
18255279
20.

Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.

Choi HJ, Kim DG, Na GH, Han JH, Hong TH, You YK.

World J Gastroenterol. 2013 Aug 7;19(29):4737-44. doi: 10.3748/wjg.v19.i29.4737.

Supplemental Content

Support Center